Table 8.

Questions and considerations in case a COVID-19 vaccine is developed

Question	Considerations
If a vaccine is developed?	What type of vaccine will it be (live/non-live, classic killed, DNA, or recombinant)? Will it need special manufacture and transport conditions (such as cold chain)? How robust will be vaccine-acquired immunity? After how many doses? How protective will it be against infection? For how long will vaccine-acquired immunity last? And hence: how often will the vaccine have to be administered? Only once? Or yearly? Will there be any adverse effects?
Acquired immunity is not very strong; hence, what is the consequence regarding herd immunity?	To achieve herd immunity, how efficient will the vaccine need to be? What proportion of the population (critical population) will need to be vaccinated? How long will it take to effectively vaccinate the critical population? Will vaccination be acceptable in the population? Or will vaccine hesitancy reduce uptake?
What are the socioeconomic implications?	Which countries will get the vaccine first (implications for LICs/LMICs)? How expensive will the vaccine be? Will vaccination be made mandatory, especially for international travel?

LICs/LMICs, low and lower middle income countries.